Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model

BMC Complementary and Alternative Medicine

Hi-Joon Park³  Seong-Uk Park¹  Jongpil Kim⁴  Songhee Jeon⁴  Hyejung Lee³  Ji-Yeun Park³  Hye Hyun Yoo²  Dae-Hyun Hahm³  Seung-Nam Kim³  Ah-Reum Doo³ 

[1] Stroke and Neurological Disorders Center, Kyung Hee University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea;Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan-si, Gyeonggi-do 426-791, Republic of Korea;Studies of Translational Acupuncture Research (STAR), Acupuncture & Meridian Science Research Center (AMSRC), Kyung Hee University, 1 Hoegi-dong, Dongdaemoon-gu, Seoul 130-701, Republic of Korea;Dongguk University Research Institute of Biotechnology, Dongguk University, 3-26, Pil Dong, Choong-Gu, Seoul 100-715, Republic of Korea

关键词: FosB;    ERK1/2;    Levodopa-induced dyskinesia;    Parkinson’s disease;    Gastrodia elata blum;   

Others  :  1220216
DOI  :  10.1186/1472-6882-14-107

 received in 2013-12-16, accepted in 2014-03-11,  发布年份 2014

【 摘 要 】

Background

Gastrodia elata Blume (GEB), commonly used medicinal herb, has been reported as a promising candidate for neurodegenerative diseases such as Parkinson’s disease. The dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), is the gold-standard drug for Parkinson’s disease, but long-term treatment results in the L-dopa-induced dyskinesia (LID). This study was undertaken to examine the beneficial effects of GEB on L-DOPA induced dyskinesia in 6-hydroxydopamine (6-OHDA)-induced experimental Parkinsonism.

Methods

We tested the effects of GEB on LID in 6-hydroxydopamine hydrochloride-hemiparkinsonian mice. To analyze the dyskinetic anomalies, we measured abnormal involuntary movement (AIM). Immunohistological analyses of pERK and FosB expressions in the striatum are performed to explore the mechanism of GEB on LID.

Results

The finding of this study demonstrated that GEB (200, 400 and 800 mg/kg) alleviated L-dopa induced AIMs in a dose-dependent manner. In each integrative AIM subtype analysis, we also found that the GEB (400 and 800 mg/kg) treatment decreased L-DOPA-induced axial, limb, orolingual, and locomotive AIMs compared to the LID group. In addition, GEB normalized the abnormal LID-induced increase of pERK1/2 and FosB, the immediate early genes of LID in the striatum.

Conclusions

In conclusion, our results provide a novel insight into the pharmacological actions of GEB that could have a benefit for PD patients through the reduction of LID.

【 授权许可】

   
2014 Doo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Brooks DJ: The early diagnosis of Parkinson’s disease. Ann Neurol 1998, 44:S10-S18.
• [2]Chase TN, Oh JD, Blanchet PJ: Neostriatal mechanisms in Parkinson’s disease. Neurology 1998, 51:S30-S35.
• [3]Chung V, Liu L, Bian Z, Zhao Z, Leuk Fong W, Kum WF, Gao J, Li M: Efficacy and safety of herbal medicines for idiopathic Parkinson’s disease: a systematic review. Movement disorders 2006, 21:1709-1715.
• [4]Bido S, Marti M, Morari M: Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem 2011, 118:1043-1055.
• [5]Leentjens AF: The role of dopamine agonists in the treatment of depression in patients with Parkinson’s disease: a systematic review. Drugs 2011, 71:273-286.
• [6]Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement disorders 2001, 16:448-458.
• [7]Blandini F, Armentero MT: New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson’s disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs 2012, 21:153-168.
• [8]Muller T, Russ H: Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin Pharmacother 2005, 7:1715-1730.
• [9]Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F: Impact of the motor complications of Parkinson’s disease on the quality of life. Movement disorders 2005, 20:224-230.
• [10]Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG: Levodopa-induced dyskinesias. Movement disorders 2007, 22:1379-1389.
• [11]Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E: Priorities in Parkinson’s disease research. Nature reviews. Drug discovery 2011, 10:377-393.
• [12]Sarchielli P, Presciutti O, Alberti A, Tarducci R, Gobbi G, Galletti F, Costa C, Eusebi P, Calabresi P: A 1H magnetic resonance spectroscopy study in patients with obstructive sleep apnea. Eur J Neurol 2008, 15:1058-1064.
• [13]Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA: Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Experimental neurology 2005, 194:66-75.
• [14]Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484-1491.
• [15]Chase TN, Oh JD: Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends in neurosciences 2000, 23:S86-S91.
• [16]Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA: Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 2009, 330:227-235.
• [17]Olanow CW, Obeso JA: Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors. Neurology 2000, 55:S72-S77.
• [18]Li M, Hu J, Li G, Xie L: The antagonism of rhizoma gastrodiae to lead-induced damage of hippocampus in rats. Zhonghua lao dong wei sheng zhi ye bing za zhi 2002, 20:331-333.
• [19]Liu ZH, Hu HT, Feng GF, Zhao ZY, Mao NY: Protective effects of gastrodin on the cellular model of Alzheimer’s disease induced by Abeta25-35. Sichuan da xue xue bao 2005, 36:537-540.
• [20]May BH, Lit M, Xue CC, Yang AW, Zhang AL, Owens MD, Head R, Cobiac L, Li CG, Hugel H, Story DF: Herbal medicine for dementia: a systematic review. Phytotherapy research 2009, 23:447-459.
• [21]Lee YS, Ha JH, Yong CS, Lee DU, Huh K, Kang YS, Lee SH, Jung MW, Kim JA: Inhibitory effects of constituents of Gastrodia elata Bl. on glutamate-induced apoptosis in IMR-32 human neuroblastoma cells. Arch Pharm Res 1999, 22:404-409.
• [22]Kim HJ, Moon KD, Oh SY, Kim SP, Lee SR: Ether fraction of methanol extracts of Gastrodia elata, a traditional medicinal herb, protects against kainic acid-induced neuronal damage in the mouse hippocampus. Neuroscience letters 2001, 314:65-68.
• [23]Kumar H, Kim IS, More SV, Kim BW, Bahk YY, Choi DK: Gastrodin protects apoptotic dopaminergic neurons in a toxin-induced Parkinson’s disease model. Evid Based Complement Alternat Med 2013, 2013:514095.
• [24]Kim HJ, Lee SR, Moon KD: Ether fraction of methanol extracts of Gastrodia elata, medicinal herb protects against neuronal cell damage after transient global ischemia in gerbils. Phytother Res 2003, 17:909-912.
• [25]Xiao YQ, Li L, You XL: Studies on chemical constituents of effective part of Gastrodia elata. Zhongguo Zhong yao za zhi 2002, 27:35-36.
• [26]An H, Kim IS, Koppula S, Kim BW, Park PJ, Lim BO, Choi WS, Lee KH, Choi DK: Protective effects of Gastrodia elata Blume on MPP + −induced cytotoxicity in human dopaminergic SH-SY5Y cells. J Ethnopharmacol 2010, 130:290-298.
• [27]Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Herve D, Greengard P, Fisone G: Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007, 27:6995-7005.
• [28]Calabresi P, Giacomini P, Centonze D, Bernardi G: Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000, 47:S60-S68.
• [29]Cenci MA, Lee CS, Bjorklund A: L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998, 10:2694-2706.
• [30]Lundblad M, Picconi B, Lindgren H, Cenci MA: A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004, 16:110-123.
• [31]Andersson M, Hilbertson A, Cenci MA: Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol Dis 1999, 6:461-474.
• [32]Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, Greengard P, Girault JA, Valjent E, Fisone G: L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 2009, 108:621-633.
• [33]Ha JH, Shin SM, Lee SK, Kim JS, Shin US, Huh K, Kim JA, Yong CS, Lee NJ, Lee DU: In vitro effects of hydroxybenzaldehydes from Gastrodia elata and their analogues on GABAergic neurotransmission, and a structure-activity correlation. Planta medica 2001, 67:877-880.
• [34]Liu J, Mori A: Antioxidant and free radical scavenging activities of Gastrodia elata Bl. and Uncaria rhynchophylla (Miq.) Jacks. Neuropharmacology 1992, 31:1287-1298.
• [35]Ahn EK, Jeon HJ, Lim EJ, Jung HJ, Park EH: Anti-inflammatory and anti-angiogenic activities of Gastrodia elata Blume. J Ethnopharmacol 2007, 110:476-482.
• [36]Hu K, Jeong JH: A convergent synthetic study of biologically active benzofuran derivatives. Arch Pharm Res 2006, 29:476-478.
• [37]Kim BW, Koppula S, Kim JW, Lim HW, Hwang JW, Kim IS, Park PJ, Choi DK: Modulation of LPS-stimulated neuroinflammation in BV-2 microglia by Gastrodia elata: 4-hydroxybenzyl alcohol is the bioactive candidate. J Ethnopharmacol 2012, 139:549-557.
• [38]Park S, da Kim S, Kang S: Gastrodia elata Blume water extracts improve insulin resistance by decreasing body fat in diet-induced obese rats: vanillin and 4-hydroxybenzaldehyde are the bioactive candidates. Eur J Nutr 2011, 50:107-118.
• [39]Niu Q, Niu P, He S: Effect of gastrodia elata on learning and memory impairment induced by aluminum in rat. Wei sheng yan jiu 2004, 33:45-48.
• [40]Wu CR, Hsieh MT, Huang SC, Peng WH, Chang YS, Chen CF: Effects of Gastrodia elata and its active constituents on scopolamine-induced amnesia in rats. Planta medica 1996, 62:317-321.
• [41]Dai JN, Zong Y, Zhong LM, Li YM, Zhang W, Bian LG, Ai QL, Liu YD, Sun J, Lu D: Gastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulated microglia via MAPK pathways. PloS one 2011, 6:e21891.
• [42]Yang P, Han Y, Gui L, Sun J, Chen YL, Song R, Guo JZ, Xie YN, Lu D, Sun L: Gastrodin attenuation of the inflammatory response in H9c2 cardiomyocytes involves inhibition of NF-kappaB and MAPKs activation via the phosphatidylinositol 3-kinase signaling. Biochemical pharmacology 2013, 85:1124-1133.
• [43]Benturquia N, Courtin C, Noble F, Marie-Claire C: Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice. Brain research 2008, 1211:1-5.